Cancer Drug Price Cap: 7 Pharma and Hospital Stocks That Could Be Affected by the 30% Trade Margin Limit
Cancer treatment in India can be expensive, with patients often bearing a significant share of medical costs. High medicine prices and mark-ups across the supply chain have raised concerns about affordability, prompting the government to introduce measures aimed at reducing the cost of essential cancer medicines.
Cancer Treatment Stocks: The Centre's decision to cap trade margins on anti-cancer drugs could affect hospital chains such as Max Healthcare, Fortis Healthcare and Apollo Hospitals Enterprise. However, Goldman Sachs noted that oncology medicines account for less than 5 percent of hospital revenue and less than 2 to 2.5 percent of EBITDA, limiting the overall impact.
Also Read: TCS, Infosys, Wipro and HCLTech in Focus: Will Suspension of Green Card Programme Raise Staffing Costs and Reduce Profit Margins?
According to Goldman Sachs, Max Healthcare and Fortis Healthcare have slightly higher exposure to the price controls. Hospitals currently earn average margins of 30 to 50 percent on oncology drugs, but could recover some losses through revised drug administration charges. Even under a bear case scenario, the EBITDA impact could remain below 2 percent.
Cancer Drug Makers: The Centre's decision to cap trade margins on non-scheduled anti-cancer drugs at 30 percent of the maximum retail price (MRP) could affect pharmaceutical companies selling cancer medicines. Sun Pharma's portfolio includes capecitabine and imatinib, while Natco Pharma markets sorafenib and pemetrexed.
Zydus Lifesciences also has an oncology portfolio that includes Tishtha, a nivolumab biosimilar used in cancer immunotherapy, and Dr. Reddy's Laboratories' Toripalimab drug.
Stocks such as Sun Pharmaceutical Industries, Natco Pharma, Dr. Reddy's Laboratories and Zydus Lifesciences could remain in focus as investors assess the policy's impact. However, these medicines are examples of the companies' portfolios and are not confirmed to be covered by the new cap. The actual impact will depend on the government's final list of medicines and the price changes applicable to each product.
Center on Cancer Drug Makers
Trade Margin Capped at 30 Percent
The Centre has decided to cap trade margins at 30 percent of the maximum retail price (MRP) for all non-scheduled anti-cancer drugs. The move is expected to be implemented later in October 2026 and aims to make cancer treatment more affordable by reducing excessive mark-ups across the supply chain.
Prices of 110 Anti-Cancer Drugs May Fall
The decision is expected to reduce the MRP of 110 anti-cancer drugs, including 35 patented medicines, by 20 to 70 percent. The extent of the price reduction will depend on the existing trade structure and mark-ups on individual medicines.
Patients May Save Rs 2,500 Crore Annually
According to the government, the move is expected to generate annual savings of approximately Rs 2,500 crore for cancer patients. Lower medicine prices could help reduce the financial burden of treatment on patients and their families, who often pay a substantial share of medical expenses out of pocket.
Branded, Generic and Imported Drugs Covered
The cap will apply to branded and generic, domestic and imported, patented and non-patented anti-cancer medicines included in the final list. The National Pharmaceutical Pricing Authority (NPPA) found that non-scheduled anti-cancer drugs carried average price mark-ups of around 170 percent, with some reaching 700 percent or more.
Move Follows Supreme Court Concerns
The decision follows the Supreme Court's September 29 concerns over inflated anti-cancer drug prices. In February 2019, a similar intervention covering 42 selected non-scheduled anti-cancer drugs reduced MRPs by up to 91 percent, with reported annual savings of Rs 984 crore across 526 brands.
Also Read: KEC International in focus after securing fresh orders worth ₹1,030 Crore
Conclusion
The Centre's decision to cap trade margins on anti-cancer drugs aims to make cancer treatment more affordable by reducing excessive mark-ups across the supply chain. While patients are expected to benefit from lower medicine prices, pharmaceutical companies and hospital chains could see changes in their pricing and pharmacy margins.
The actual impact on these stocks will become clearer once the final list of covered medicines is released, as the effect will depend on each company's exposure to the affected drugs.